Assessment of VL-specific antibodies by commercial (TECAN, NovaLisa) and rKLi8.3 prototype ELISA. (A) Sera from VL patients infected with L. donovani/L. infantum (n = 8); cutaneous leishmaniasis (CL) patients infected with L. tropica (n = 6), L. major (n = 6), L. brasiliensis (n = 2); and Chagas disease patients infected with T. cruzi (n = 8) were tested. The manufacturer-defined borderline zone is indicated by red lines; data within were considered negative. (B) ROC curve analysis of TECAN, NovaLisa, and rKLi8.3 prototype ELISA.